Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Leukemia
|
September 16, 1998
Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study
G Marit, F Thiessard, C Faberes, et al.
Leukemia & Lymphoma
|
April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte
C Gisselbrecht, C Haioun, E Lepage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma
G Marit, C Faberes, J L Pico, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment
J Bienvenu, R Chvetzoff, G Salles, et al.
European Cytokine Network
|
March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission
D Blaise, M Attal, J Reiffers, et al.
Leukemia & Lymphoma
|
November 9, 2001
Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group
E Jourdan, J Reiffers, A M Stoppa, et al.
Blood
|
October 25, 2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease
V Leblond, V Lévy, F Maloisel, et al.
Bone Marrow Transplantation
|
November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)
M Mohty, M Attal, G Marit, et al.
Bone Marrow Transplantation
|
November 12, 2014
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
H W Auner, R Szydlo, J Hoek, et al.
Leukemia
|
December 1, 1996
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study
J Reiffers, A M Stoppa, M Attal, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Leukemia
|
September 16, 1998
Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study
G Marit, F Thiessard, C Faberes, et al.
Leukemia & Lymphoma
|
April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte
C Gisselbrecht, C Haioun, E Lepage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma
G Marit, C Faberes, J L Pico, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment
J Bienvenu, R Chvetzoff, G Salles, et al.
European Cytokine Network
|
March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission
D Blaise, M Attal, J Reiffers, et al.
Leukemia & Lymphoma
|
November 9, 2001
Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group
E Jourdan, J Reiffers, A M Stoppa, et al.
Blood
|
October 25, 2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease
V Leblond, V Lévy, F Maloisel, et al.
Bone Marrow Transplantation
|
November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)
M Mohty, M Attal, G Marit, et al.
Bone Marrow Transplantation
|
November 12, 2014
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
H W Auner, R Szydlo, J Hoek, et al.
Leukemia
|
December 1, 1996
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study
J Reiffers, A M Stoppa, M Attal, et al.
Page
of 11